雷:其使用的更新acid-related紊乱。

文章的细节

引用

复制到剪贴板

卡斯韦尔CI,果阿吉隆坡

雷:其使用的更新acid-related紊乱。

药。2001;61 (15):2327 - 56。

PubMed ID

11772142 (在PubMed

]

文摘

雷是一个胃质子泵抑制剂。它会导致剂量依赖性抑制胃酸分泌。在8周的研究中,患者gastro-oesophageal反流病(GORD),雷20毫克/天或10毫克每天两次和奥美拉唑一样有效,优于雷尼替丁治疗的GORD。症状缓解与雷优于安慰剂组和雷尼替丁和类似于奥美拉唑。长期试验中雷10毫克/天是类似于奥美拉唑20毫克/天在2年的一项研究中,优于安慰剂在1年的研究中,在维护患者的治疗和预防症状的GORD治好了。在nonerosive GORD,四周的研究表明雷比安慰剂更有效缓解胃灼热和各种其他胃肠道症状。患者巴雷特食管的数据表明雷20毫克/天可能比安慰剂更有效的维持治疗相关的食管炎治疗后1年。一周三重幽门螺杆菌根除治疗雷+克拉霉素、阿莫西林实现根除率> = 85%。雷时有效的用兰索拉唑和奥美拉唑作为三联疗法的一部分为根除幽门螺杆菌方案。根除率> 90%时达到雷20至40毫克/天是包括作为四根除方案的一部分。 As monotherapy for peptic ulcer healing and symptom relief, 4- to 8-week studies have shown rabeprazole 10 to 40 mg/day to be superior to placebo and ranitidine and have similar efficacy to omeprazole. Preliminary 1-year data among 16 patients with Zollinger-Ellison syndrome suggest rabeprazole 60 to 120 mg/day can resolve and prevent the recurrence of symptoms and endoscopic lesions associated with this condition. In clinical trials of up to 2 years' duration the tolerability of rabeprazole is similar to that of placebo, ranitidine and omeprazole. Common adverse events assigned to rabeprazole have been diarrhoea, headache, rhinitis, nausea, pharyngitis and abdominal pain. Histological changes and increases in serum gastrin levels were unremarkable and typical of proton pump inhibitors. No dosage adjustment is necessary in renal and mild to moderate hepatic impairment. CONCLUSION: Rabeprazole is a well tolerated proton pump inhibitor. It has proven efficacy in healing, symptom relief and prevention of relapse of peptic ulcers and GORD and can form part of effective H. pylori eradication regimens. It is an important alternative to H(2) antagonists and an additional treatment option to other proton pump inhibitors in the management of acid-related disorders.

beplay体育安全吗DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
雷	Potassium-transporting atp酶α链1	蛋白质	人类	是的	抑制剂	细节